Yescarta (Axicabtagene Ciloleucel) Denied: Appealing CAR-T Coverage for LBCL and Follicular Lymphoma

Yescarta (axicabtagene ciloleucel) is a CAR-T cell therapy FDA-approved for large B-cell lymphoma (LBCL, including DLBCL, HGBCL, PMBCL, and FL3B) in adults with relapsed or refractory disease after at least one line of chemoimmunotherapy, relapsed or refractory follicular lymphoma (FL grade 1–3A) after at least two prior lines of systemic therapy, and as second-line therapy for LBCL that is primary refractory or relapses within 12 months of first-line treatment. The second-line approval (from the ZUMA-7 trial) significantly expanded Yescarta's coverage territory — and created new battlegrounds with insurers who have not updated their coverage policies.

Why Yescarta Gets Denied

Prior line requirements. The second-line LBCL approval is the most contested area. Prior to ZUMA-7 and FDA's 2022 approval expansion, CAR-T was a third-line-or-later therapy. Many insurer coverage policies still reflect the older requirement for two or more prior lines of therapy. If your oncologist recommends Yescarta as second-line therapy for primary refractory or early-relapsed LBCL, the denial may simply reflect an outdated coverage policy.

Definition of "chemoimmunotherapy" line. Insurers sometimes dispute whether a patient received a complete qualifying line of chemoimmunotherapy. If first-line treatment was abbreviated due to toxicity, if the patient received a different induction regimen, or if the regimen was modified in a way the insurer argues does not qualify as a full "line," coverage can be denied.

Follicular lymphoma eligibility. Yescarta's FL approval requires at least two prior systemic therapy lines. Insurers may dispute whether rituximab maintenance constitutes a separate line or whether a specific regimen qualifies. Clinical records should document each regimen separately with clear progression/relapse documentation between lines.

Apheresis authorization separate from CAR-T. The apheresis procedure (collection of T-cells) must be pre-authorized. This is a separate authorization from the CAR-T infusion itself in some plans. Denials occur when apheresis proceeds before the insurer has approved the full CAR-T episode of care. Ideally, both authorizations should be obtained simultaneously.

Manufacturing failure replacement. In rare cases, the manufacturing process fails and a replacement product must be manufactured. Insurers may not have clear policies for coverage of manufacturing failure replacements. This scenario requires direct escalation to the insurer's medical director.

Building the Yescarta Appeal

Document primary refractory or early relapsed LBCL. For second-line use, the FDA approval applies to:

• LBCL refractory to first-line chemoimmunotherapy (no complete or partial response achieved)
• LBCL relapsing within 12 months of completing first-line chemoimmunotherapy

Your oncologist's letter should state explicitly which of these categories applies, supported by:

• PET-CT results showing no response or early progression
• Pathology confirming LBCL histology
• Timeline from first-line start to progression/relapse date

For third-line-or-later use. Document the full sequence of prior lines with regimen names, cycle counts, response categories, and dates of progression for each line.

Cite the ZUMA-7 trial. For second-line use, ZUMA-7 demonstrated statistically significant improvement in event-free survival compared to standard of care (salvage chemoimmunotherapy followed by autologous stem cell transplant). This is level 1 evidence. If the insurer's policy hasn't been updated to reflect the 2022 approval, cite the approval date and the trial data directly.

Include the treating center's REMS certification. Yescarta, like all CAR-T therapies, is only available at authorized treatment centers certified under the YESCARTA REMS program. Confirm and document the center's certification in the Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization.

Request expedited processing. LBCL is an aggressive malignancy with short natural history without treatment. File for expedited review from the start. Each day of delay increases the risk of disease progression that could make the patient ineligible for CAR-T infusion.

Managing the Bridging Therapy Authorization

Between apheresis and infusion (typically 3–4 weeks for manufacturing), rapidly progressing LBCL often requires bridging chemotherapy. The prior authorization for Yescarta should explicitly request approval for bridging therapy options — typically gentler regimens like lenalidomide, polatuzumab vedotin monotherapy, or low-dose steroids — to be covered pending the infusion authorization.

Fight Back With ClaimBack

Yescarta denials can interrupt a precisely timed treatment sequence where days matter. ClaimBack helps you build urgency-appropriate, oncology-specific appeals that address the exact line-of-therapy and eligibility arguments insurers use.

Start your Yescarta appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal: What's the Difference?